Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project and at year-end, the number had increased to four”, commented CEO Per Norlén.Significant events October – December• The first patient was dosed in a Phase I study with the drug candidate ATOR-1017 that is in development for the treatment of metastasized cancer.• Dr Malin Carlsson was appointed Chief Operating Officer.• ALG.APV-527 and ATOR-1017 new preclinical data were presented at the scientific conference SITC 2019.Events after the end of the